MEREO BIOPHARMA GROUP PLC Adjustments For Income Tax Expense
MEREO BIOPHARMA GROUP PLC (MREO) reported Adjustments For Income Tax Expense of -GBP 1.53 million for the 6-month period ending 2022-06-30, per its 6-K filed 2022-11-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:AdjustmentsForIncomeTaxExpense · last filed 2022-11-02
- 2022-06-30: Adjustments For Income Tax Expense 6 month -1.53M GBP.
| Period end | Adjustments For Income Tax Expense 6 month |
|---|---|
| 2022-06-30 | -1.53M GBP 6-K · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |